AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31145415 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate for both intravenous and subcutaneous administration
Number of subjects: 40
Study 31145415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of PF-06801591
Number of subjects: 40
Study 31145415 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1 receptor occupancy
Number of subjects: 40
Study 31145418 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX and losartan for 8 cycles followed by chemoradiotherapy (short-course or long-course depending on resectability)
Number of subjects: 49
Study 31145440 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II Retinal Prosthesis
Number of subjects: 47
Study 31145440 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II Retinal Prosthesis On
Number of subjects: 47
Study 31145440 — intervention group
Group type: COMPARATOR
Intervention: Argus II Retinal Prosthesis Off
Number of subjects: 47
Study 31146167 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomal miR-141-3p
Number of subjects: 93
Study 31146167 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosomal miR-375
Number of subjects: 93
Study 31146167 — intervention group
Group type: EXPERIMENTAL
Intervention: High exosomal miR-141-3p
Number of subjects: 93
Study 31146700 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD7 gene variants
Number of subjects: 12
Study 31146700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial MRI analysis
Number of subjects: 12
Study 31146732 — intervention group
Group type: EXPERIMENTAL
Intervention: XN-30
Number of subjects: 16
Study 31146732 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 16
Study 31146732 — intervention group
Group type: COMPARATOR
Intervention: Malaria rapid diagnostic tests (HRP-2/pLDH)
Number of subjects: 16
Study 31146808 — intervention group
Group type: EXPERIMENTAL
Intervention: Valve-in-valve TAVR
Number of subjects: 365
Study 31147129 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 102
Study 31147139 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith Dissection Endovascular System (William Cook Europe)
Number of subjects: 86
Study 31147146 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by concurrent cisplatin and radiation therapy (CRT)
Number of subjects: 30
Study 31147302 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1837 (three increasing dosages twice-daily for two 7-day and one 14-day period)
Number of subjects: 32
Study 31147302 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG1837 (after one-week ivacaftor washout)
Number of subjects: 32
Study 31147302 — intervention group
Group type: COMPARATOR
Intervention: ivacaftor (one-week washout)
Number of subjects: 32
Study 31147307 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative aortography using videodensitometry
Number of subjects: 354
Study 31147307 — intervention group
Group type: COMPARATOR
Intervention: Previous validation studies (RESPOND population)
Number of subjects: 354
Study 31147307 — intervention group
Group type: COMPARATOR
Intervention: CT planning strategy
Number of subjects: 354
Study 31147307 — intervention group
Group type: COMPARATOR
Intervention: Teng's rule planning strategy
Number of subjects: 354
Study 31147307 — intervention group
Group type: COMPARATOR
Intervention: Circle planning strategy
Number of subjects: 354
Study 31147307 — intervention group
Group type: COMPARATOR
Intervention: 3mensio planning strategy
Number of subjects: 354
Study 31147686 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum (OPC)
Number of subjects: 1006
Study 31147927 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-targeted PET/CT
Number of subjects: 14
Study 31147927 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 14
Study 31148056 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative or surgical treatment for LUTS/BPH
Number of subjects: 83
Study 31148056 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 83
Study 31148336 — intervention group
Group type: EXPERIMENTAL
Intervention: RIP3 promoter variant rs3212247
Number of subjects: 3194
Study 31148336 — intervention group
Group type: EXPERIMENTAL
Intervention: RIP3 promoter variant rs3212247 CC genotype
Number of subjects: 3194
Study 31148336 — intervention group
Group type: COMPARATOR
Intervention: RIP3 missense variant rs3212254
Number of subjects: 3194
Study 31148501 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise motivation
Number of subjects: 166
Study 31148501 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise attitudes
Number of subjects: 166
Study 31148501 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise self-concept
Number of subjects: 166
Study 31148501 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise support from friends
Number of subjects: 166
Study 31148501 — intervention group
Group type: EXPERIMENTAL
Intervention: Places for walking and cycling
Number of subjects: 166
Study 31148544 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated mobile phone-based personalized messages (SMS or automated call)
Number of subjects: 250
Study 31148544 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 250
Study 31148544 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of automated SMS text or calls
Number of subjects: 250
Study 31150484 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive primary school-based health intervention program
Number of subjects: 380
Study 31150484 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched schools)
Number of subjects: 380
Study 31150817 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD with shock energy of 65 J
Number of subjects: 570
Study 31150817 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD with a vector programmed with a 2× gain
Number of subjects: 570
Study 31151383 — intervention group
Group type: EXPERIMENTAL
Intervention: Reveal LINQ ICM insertion
Number of subjects: 191
Study 31151405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 25M pCPC
Number of subjects: 0
Study 31151405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 50M pCPC
Number of subjects: 0
Study 31151405 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary infusion of vehicle (Control)
Number of subjects: 0
Study 31151409 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week community-based pulmonary rehabilitation (PR)
Number of subjects: 73
Study 31151438 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based palliative care intervention consisting of five 2-h seminars during a 6-month period.
Number of subjects: 365
Study 31151438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 365
Study 31151483 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical trial (CREST-2)
Number of subjects: 235
Study 31151483 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic trials (NAVIGATE-ESUS, DATAS-II)
Number of subjects: 235
Study 31151483 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomized external monitoring device study (PROPHECY)
Number of subjects: 235
Study 31151483 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 235
Study 31151904 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 50
Study 31151984 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical HCT/kidney transplantation with fludarabine, cyclophosphamide, total-body irradiation, and GVHD prophylaxis (post-HCT cyclophosphamide, tacrolimus, mycophenolate mofetil)
Number of subjects: 6
Study 31152037 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII Fc (rFVIIIFc)
Number of subjects: 350
Study 31152037 — intervention group
Group type: COMPARATOR
Intervention: Conventional factor products
Number of subjects: 350
Study 31152361 — intervention group
Group type: EXPERIMENTAL
Intervention: Online weight management program plus population health management (PHM) support from primary care practices
Number of subjects: 13
Study 31152361 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed online program
Number of subjects: 13
Study 31152555 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine administered twice daily for 3 days
Number of subjects: 397
Study 31152670 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of the Alternate Dietary Inflammatory Index (ADII)
Number of subjects: 26730
Study 31152670 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of the ADII among women
Number of subjects: 26730
Study 31152670 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of the ADII among middle-age adults
Number of subjects: 26730
Study 31152670 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of the ADII among participants with BMI ≥25
Number of subjects: 26730
Study 31152705 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH intervention (combined outpatient and home PT with app and tablet)
Number of subjects: 75
Study 31152705 — intervention group
Group type: COMPARATOR
Intervention: Control group (propensity matched controls, n=100)
Number of subjects: 75
Study 31152738 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided drainage with the newly designed LAMS (Niti-S SPAXUS)
Number of subjects: 34
Study 31153765 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent upper respiratory infections, gastroesophageal reflux, and neck trauma as extrinsic risk factors for SD.
Number of subjects: 186
Study 31153765 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI analysis of a subset of SD patients.
Number of subjects: 186
Study 31153920 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct and indirect costs incurred by caregivers in El Salvador
Number of subjects: 638
Study 31153920 — intervention group
Group type: EXPERIMENTAL
Intervention: Government-paid hospitalization costs in El Salvador
Number of subjects: 638
Study 31153920 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall societal cost of severe ARI in El Salvador
Number of subjects: 638
Study 31153920 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct and indirect costs incurred by caregivers in Panama
Number of subjects: 638
Study 31153920 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care system costs in Panama
Number of subjects: 638
Study 31153920 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall societal cost of severe ARI in Panama
Number of subjects: 638
Study 31154041 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive symptom and comorbidity questionnaires, spirometry, CT scans of the chest, and genetic and biomarker profiling
Number of subjects: 10000
Study 31154312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Clinical Trials (CCT)
Number of subjects: 199
Study 31154457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 200 mg, administered intravenously every 3 weeks for up to 35 doses.
Number of subjects: 30
Study 31154522 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in hypoxia
Number of subjects: 37
Study 31154634 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR20 achievement
Number of subjects: 780
Study 31154634 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA achievement
Number of subjects: 780
Study 31154634 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ-DI MCID achievement (improvement ≥ 0.35)
Number of subjects: 780
Study 31154634 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenteeism improvement
Number of subjects: 780
Study 31154634 — intervention group
Group type: EXPERIMENTAL
Intervention: Work productivity loss improvement
Number of subjects: 780
Study 31154634 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity impairment improvement
Number of subjects: 780
Study 31154919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks)
Number of subjects: 550
Study 31154919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 550
Study 31154995 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling on appropriate infant feeding and WASH practices for six months (monthly visits)
Number of subjects: 20
Study 31155412 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31155600 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV), administered in a three-vaccination regimen (Day 1, Months 2 and 6)
Number of subjects: 100
Study 31155658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics data from Metabolon, Inc. (14 cohorts)
Number of subjects: 136000
Study 31155658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics data from the Broad Institute (15 cohorts)
Number of subjects: 136000
Study 31155932 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction model for life-threatening ventricular tachyarrhythmia (LTVTA)
Number of subjects: 839
Study 31155932 — intervention group
Group type: COMPARATOR
Intervention: Risk prediction model for LTVTA
Number of subjects: 839
Study 31156069 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported cigarette smoking in adults with ADHD
Number of subjects: 0
Study 31156069 — intervention group
Group type: COMPARATOR
Intervention: Self-reported cigarette smoking in adults without ADHD
Number of subjects: 0
Study 31156406 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 31156406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31156538 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Phenobarbital
Number of subjects: 0
Study 31156538 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Phenytoin
Number of subjects: 0
Study 31156861 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy care intervention involving motivational interviews, delivered by community pharmacists face-to-face or by telephone, as part of the New Medicine Service or a Medication Usage Review, lasting 15-20 minutes.
Number of subjects: 71
Study 31156861 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 71
Study 31157039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care programme focusing on resolving potential drug-related problems initiated at the emergency department
Number of subjects: 118
Study 31157039 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study 31157074 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mM trisodium citrate solution
Number of subjects: 2
Study 31157074 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mM trisodium citrate solution
Number of subjects: 2
Study 31157074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 35 mM and 90 mM trisodium citrate solutions
Number of subjects: 2
Study 31157595 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 401
Study 31157595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective frailty index (FI)
Number of subjects: 401
Study 31157595 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective frailty index (FI)
Number of subjects: 401
Study 31157653 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell transfusion (intra-operative)
Number of subjects: 61
Study 31157653 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell transfusion (day 1 or 2)
Number of subjects: 61
Study 31157653 — intervention group
Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 61
Study 31157653 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell transfusion
Number of subjects: 61
Study 31157681 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants (younger children)
Number of subjects: 204
Study 31157746 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.i.d. for 5 days
Number of subjects: 60
Study 31157864 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention with electronic tablet screener and motivational/educational videos; 2,764 smokers consented at visits.
Number of subjects: 6885
Study 31157864 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention with electronic tablet screener; 2,764 smokers consented at visits.
Number of subjects: 6885
Study 31157864 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic screening for tobacco use; integrated into pediatric practice.
Number of subjects: 6885
Study 31158075 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glycosaminoglycan (GAG) score
Number of subjects: 175
Study 31158075 — intervention group
Group type: EXPERIMENTAL
Intervention: Total chondroitin sulfate concentration
Number of subjects: 175
Study 31158075 — intervention group
Group type: COMPARATOR
Intervention: GAG scores
Number of subjects: 175
Study 31158230 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROD biparametric MRI (bpMRI)
Number of subjects: 364
Study 31158720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 144
Study 31158720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 31159741 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital multiplexed gene expression platform
Number of subjects: 96
Study 31159741 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-Seq
Number of subjects: 96
Study 31159741 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual PAM50 genes
Number of subjects: 96
Study 31159801 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized structured dietary education for weight management (13 ± 5 sessions over 427 ± 223 days)
Number of subjects: 206
Study 31159802 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 38
Study 31159810 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Friends - Fun With New Foods® intervention delivered over 12 weeks by trained preschool teachers
Number of subjects: 250
Study 31159810 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Friends - Fun With New Foods® intervention
Number of subjects: 250
Study 31159810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 31159817 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (157 patients)
Number of subjects: 910
Study 31159817 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 910
Study 31159873 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD (n = 65)
Number of subjects: 138
Study 31159873 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD APOE ε4 carriers
Number of subjects: 138
Study 31159873 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD APOE ε4 non-carriers
Number of subjects: 138
Study 31159873 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 73)
Number of subjects: 138
Study 31160198 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinsertion computed tomography (CT)
Number of subjects: 22
Study 31160198 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic literature review and meta-analysis
Number of subjects: 22
Study 31160355 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic characterization of well-differentiated grade 3 pancreatic neuroendocrine tumor
Number of subjects: 0
Study 31160383 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 (oral mTORC1/2 inhibitor) combined with TAK-117 (PI3Kα inhibitor)
Number of subjects: 0
Study 31160383 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-228 (oral mTORC1/2 inhibitor) combined with paclitaxel (chemotherapy)
Number of subjects: 0
Study 31160680 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving stimuli
Number of subjects: 22
Study 31160680 — intervention group
Group type: COMPARATOR
Intervention: Static stimuli
Number of subjects: 22
Study 31161046 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (25%) boluses
Number of subjects: 0
Study 31161046 — intervention group
Group type: COMPARATOR
Intervention: Normal saline fluid boluses (placebo)
Number of subjects: 0
Study 31161044 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding hip screw (SHS) and vitamin D supplementation (4000 IU daily for 6 months)
Number of subjects: 60
Study 31161044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous screws and vitamin D supplementation (4000 IU daily for 6 months)
Number of subjects: 60
Study 31161044 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw (SHS) and placebo
Number of subjects: 60
Study 31161044 — intervention group
Group type: COMPARATOR
Intervention: Cancellous screws and placebo
Number of subjects: 60
Study 31161593 — intervention group
Group type: EXPERIMENTAL
Intervention: VFA-H group
Number of subjects: 276
Study 31161593 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-H group
Number of subjects: 276
Study 31161593 — intervention group
Group type: EXPERIMENTAL
Intervention: VFA
Number of subjects: 276
Study 31161706 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study 31161734 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 2 mg/kg subcutaneously every 8 weeks (4 mg/kg for NOMID patients)
Number of subjects: 17
Study 31161734 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 17
Study 31161972 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrashort echo time (UTE) MRI
Number of subjects: 38
Study 31161972 — intervention group
Group type: COMPARATOR
Intervention: CT (reference standard)
Number of subjects: 38
Study 31163298 — intervention group
Group type: EXPERIMENTAL
Intervention: LO-V30M
Number of subjects: 96
Study 31163440 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary pellicle from female subjects
Number of subjects: 50
Study 31163440 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary pellicle from male subjects
Number of subjects: 50
Study 31163440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no salivary pellicle)
Number of subjects: 50
Study 31163675 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment using Bayley Scales of Infant Development (BSID) and Autism Diagnostic Observation Schedule (ADOS)
Number of subjects: 82
Study 31163675 — intervention group
Group type: EXPERIMENTAL
Intervention: Total score of ADOS at 12 months
Number of subjects: 82